EMED Subsidiary Closes $8 Million Equity Financing
EMED Technologies, a global leader in drug delivery and infusion therapy innovation, today announced that its subsidiary has closed a successful $8 million equity investment funding round led by a multibillion dollar healthcare company.
The raise strengthens the Subsidiary's balance sheet and supports the next phase of its strategic expansion. The financing reflects strong investor confidence in the Company's technological and operating platform, execution track record, and long-term growth potential.
Proceeds from the raise will be used to support organizational scale, product expansion, and broader strategic initiatives aligned with EMED's long-term objectives in the drug delivery space.
"This capital raise represents an important milestone and reinforces the strategic value of this platform within EMED's broader portfolio. It positions the organization to execute its growth strategy with discipline while maintaining operational flexibility."
Paul LambertChief Executive Officer, EMED Technologies
EMED's subsidiary structure preserves focus within its core drug delivery business while siloing the ability to responsibly pursue growth opportunities that are complementary to that core. This approach maintains governance and operating discipline at the parent level, while allowing adjacent initiatives to develop independently without introducing risk or distraction to EMED's established platform.
For more information about EMED's full portfolio of infusion solutions, visit emedtc.com.
About EMED
EMED Technologies is an industry leader in the design, manufacture, and distribution of cutting-edge medical devices. For two decades, EMED Technologies has worked with clinicians, inventors, and medical companies to develop innovative medical products. Today, we are proud that both patients and clinicians can benefit from the fruits of our labor because we offer a wide variety of products and services that improve therapies and enhance clinical benefits. With our dynamic team of professionals, EMED continues to work with clinicians to understand their requirements and improve upon available technologies. In addition to novel technology, EMED is proud to offer licensing agreements for patented and proprietary technologies.
Media contact
For media inquiries, please contact info@emedtc.com.
Original release
The full press release is available on PR Newswire.